-
AJH: Sutizumab can effectively prevent the exacerbation of hemolytic anemia in patients with cold agglutinin disease undergoing major surgery
Time of Update: 2021-12-01
A foreign research team described a white male who had a 10-year history of coronary heart disease (CHD), with three right coronary artery (RCA) stents for myocardial infarction as a manifestationSutizumab is a complement c1 inhibitor that can selectively block classic complement activation, but retains the alternative and lectin pathways .
-
Blood: sutimlimab therapy improves severe hemolytic anemia in cold agglutinin disease
Time of Update: 2021-06-21
Bernd Jilma of the Medical University of Vienna, said: "The drug is well tolerated, resulting in a clinically significant increase in hemoglobin levels, and eliminating the need for blood transfusions, even for patients who have failed many previous treatments.
-
NEJM: Sutimlimab is effective in treating cold agglutinin disease
Time of Update: 2021-04-17
Sutimlimab can rapidly improve the symptoms of hemolysis in patients with cold agglutinin disease by selectively inhibiting the upstream target of the classical complement pathway , increase hemoglobin levels and reduce fatigue.
-
of black kidney bean agglutinin induced by acidic pH protonation
Time of Update: 2021-03-17
However, kidney beans contain high levels of lectins, which can easily cause food allergies in humans.
-
The Use of Soybean Agglutinin (SBA) for Bone Marrow (BM) Purging and Hematopoietic Progenitor Cell Enrichment in Clinical Bone Marrow Transplantation
Time of Update: 2021-03-07
SBA binds approx 60-90% of bone marrow mononuclear cells, including mature myeloid, erythroid, andlymphoid cells, but has very low binding affinity and no toxic effect to the human hematopoietic progenitor cells.